ERBB2 and breast cancer: However, new therapy approaches including antibodies against HER2 (trastuzumab and pertuzumab), reversible and irreversible HER2 enzyme inhibitors (lapatinib, neratinib (for example)), and antibody-drug conjugates (ado-trastuzumab emtansine and fam-trastuzumab-deruxtecan-nxki) have changed the life history of HER2 + BC to a much more favorable outcome [7–11].